Neovaskuläre altersabhängige Makuladegeneration in Deutschland: Beinträchtigung der lebensqualität und ihre finanziellen auswirkungen

Translated title of the contribution: Neovascular age-related macular degeneration in Germany: EEEncroachment on the quality of life and the financial implications

D. Pauleikhoff, A. Scheider, P. Wiedmann, F. Gelisken, H. P.N. Scholl, I. Roider, A. Mohr, G. Zlateva, X. Xu

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Background: Approximately 35,000 cases of neovascular age-related macular degeneration (AMD) occur annually in Germany. The neovascular form of AMD (NV-AMD) is responsible for severe vision loss associated with the disease in 90% of the cases. This study was conducted to assess the humanistic and economic burden of NV-AMD in the German population. Methods: A cross-sectional, observational study of subject self-reported functional health, well-being, and disease burden among elderly subjects with (n=83) and without (n=93) NV-AMD in Germany was conducted. Patients participated in telephone surveys involving the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25), the EuroQol (EQ-5D), the Hospital Anxiety and Depression Scale (HADS), and also reported history of falls, fractures, and healthcare resource utilization. Furthermore, the healthcare utilization and unit costs for the NV-AMD patients were calculated. Results: The mean age of NV-AMD patients was 77.2 years and 64% were female. NV-AMD patients reported significantly worse vision-related function and overall well-being than controls (adjusted mean scores: NEI-VFQ-25 overall scale: 51.3 vs 96.3; p<0.0001) and significantly more depression symptoms than controls (HADS depression: 6.2 vs. 2.7; p<0.0001). NV-AMD patients also reported that the need for assistance with daily activities was more than 10 times greater compared to controls (26.5% vs. 2.2%; p<0.0001) and the prevalence of falls was 3 times that of the control group (13.3% vs 4.3%; p=0.031). Annual NV-AMD costs per patient were € 9871, 6 times that of elderly patients without NV-AMD (€ 1559). Of the NV-AMD costs one-half were direct non-medical-related costs (assistance of ADL or social benefit) and one-third were direct medical costs. Conclusions: NV-AMD is associated with decreased functional abilities and quality of life, which result in an increase in healthcare resource utilization. Consequently, costs were higher for NV-AMD patients compared to controls. These findings emphasize the need for new NV-AMD treatments that will prevent vision loss and progression to blindness, and lessen the ensuing economic burden. Sponsored by Pfizer Inc. New York, US

Translated title of the contributionNeovascular age-related macular degeneration in Germany: EEEncroachment on the quality of life and the financial implications
Original languageGerman
Pages (from-to)242-251
Number of pages10
Issue number3
StatePublished - Mar 2009
Externally publishedYes


  • Decreased functional abilities
  • Decreased quality of life
  • Economic burden
  • Humanistic burden
  • Neovascular age-related macular degeneration

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Neovascular age-related macular degeneration in Germany: EEEncroachment on the quality of life and the financial implications'. Together they form a unique fingerprint.

Cite this